Drug Profile
AVE 3085
Alternative Names: AVE3085Latest Information Update: 17 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Heart failure therapies
- Mechanism of Action Nitric oxide synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 13 Feb 2007 Phase-I clinical trials in Congestive heart failure in Europe (unspecified route)
- 16 Nov 2005 Preclinical trials in Congestive heart failure in Europe (unspecified route)